OTCM
BXMPY
Market cap293mUSD
, Last price
USD
Name
Beximco Pharmaceuticals Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1976 and headquartered in Dhaka, Bangladesh, Beximco Pharmaceuticals Limited is a prominent company engaged in the production and distribution of generic pharmaceutical formulations and active pharmaceutical ingredients (APIs). The firm’s extensive product line addresses a wide range of therapeutic areas, including treatments for allergic disorders, pain and fever, various infections (antibacterial and antiviral), cardiovascular conditions, central nervous system ailments, respiratory illnesses, endocrine disorders, diabetes, gastrointestinal problems, hormonal therapies, oncology, musculoskeletal issues, and skin conditions. Its offerings also encompass eye care products, vitamin and mineral supplements, and intravenous fluids. These medications are supplied in a comprehensive array of dosage forms, such as solids, liquids, creams, ointments, suppositories, metered-dose and dry powder inhalers, nasal sprays, sterile injectables (including lyophilized forms), and large volume intravenous fluids. Beyond its own diverse portfolio, Beximco Pharmaceuticals provides contract manufacturing services to other companies and actively exports its products internationally.
Valuation
Title BDT in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||